ARWR Valuation Metrics
FCF$156.89M
FCF Growth Rate-0.43%
EPS Growth (CAGR)—
WACC10.00%
Arrowhead Pharmaceuticals Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.
Did you know?
Capital expenditures decreased by 84% from FY24 to FY25.
Current Price
$74.81
+1.81%Profile
Valuation (TTM)
Market Cap$10.16B
P/E50.23
EV—
P/B21.80
Shares Out135.81M
P/Sales9.31
Revenue$1.09B
EV/EBITDA29.30
Arrowhead Pharmaceuticals Inc (ARWR) Valuation
Fair Value Models
Graham Number, PEG-based, and Earnings-based models
View Fair Value →ARWR Valuation & Fair Value Analysis
Arrowhead Pharmaceuticals Inc (ARWR) valuation analysis using multiple fair value methodologies. GoodMoat calculates a blended fair value target using discounted cash flow (DCF) analysis, the Graham Number, and earnings-based valuation models.
The price-to-earnings (P/E) ratio is 50.23. Price-to-book ratio is 21.80. Price-to-sales ratio is 9.31. Enterprise value to EBITDA is 29.30. PEG ratio is -0.43.
GoodMoat's valuation models include the Graham Number (based on EPS and book value), an earnings-based model (discounted future EPS), and a PEG-adjusted valuation. The three models are averaged to produce a blended fair value estimate. Use these tools alongside the DCF calculator and reverse DCF to form a comprehensive view of Arrowhead Pharmaceuticals Inc's intrinsic value.